GC Biopharma's Recombinant Anthrax Vaccine, BARYTHRAX, Demonstrates Safety and Immunogenicity in Phase 2 Data, Published in 'Vaccine'

GC Biopharma, a leading global pharmaceutical company based in South Korea, announced today that the Phase 2 clinical trial results for its anthrax vaccine 'BARYTHRAX inj. (GC1109)' have been ...
HealthDay on MSN

Two-Dose Recombinant Zoster Vaccine Effective in Older Adults, Regardless of Prior Vaccination

Two RZV doses are effective among older adults, with similar vaccine efficacy found among immunocompetent vs immunocompromised individuals.
News Medical

Recombinant factor C endotoxin testing: All you need to know

Endotoxin testing is critical for quality control in drug production, as it has a direct impact on pharmaceutical safety and effectiveness. Traditionally Limulus Amebocyte Lysate (LAL) testing is used ...
Pharmabiz

EMA committee issues positive opinion to support the approval of GSK’s recombinant zoster vaccine, Shingrix in a prefilled syringe

EMA committee issues positive opinion to support the approval of GSK’s recombinant zoster vaccine, Shingrix in a prefilled syringe: London, UK Wednesday, October 22, 2025, 16:00 ...